Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Parmiani

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Seminars in Cancer Biology|March 6, 2004
Immunotherapy of melanomaGiorgio Parmiani, Chiara Castelli, Licia Rivoltini, et al.
Dermatology (Basel, Switzerland)|June 6, 2013
Follow-up of melanoma: a survey of Italian hospitalsAlessandro Testori, Vanna Chiarion-Sileni, Ignazio Stanganelli, et al.
Immunological Reviews|November 26, 2002
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interactionLicia Rivoltini, Matteo Carrabba, Veronica Huber, et al.
Cancer Gene Therapy|March 16, 2002
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccineMarilisa Carsana, Gabrina Tragni, Gabriella Nicolini, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Nature Reviews. Clinical Oncology|July 9, 2014
Therapeutic vaccines for cancer: an overview of clinical trialsIgnacio Melero, Gustav Gaudernack, Winald Gerritsen, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2011
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyTonia Mazzarella, Valeria Cambiaghi, Nathalie Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 15, 2002
Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cellsMichele Maio, Ester Fonsatti, Elda Lamaj, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigenLuisa Novellino, Nicolina Renkvist, Francesca Rini, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Seminars in Cancer Biology|March 6, 2004
Immunotherapy of melanomaGiorgio Parmiani, Chiara Castelli, Licia Rivoltini, et al.
Dermatology (Basel, Switzerland)|June 6, 2013
Follow-up of melanoma: a survey of Italian hospitalsAlessandro Testori, Vanna Chiarion-Sileni, Ignazio Stanganelli, et al.
Immunological Reviews|November 26, 2002
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interactionLicia Rivoltini, Matteo Carrabba, Veronica Huber, et al.
Cancer Gene Therapy|March 16, 2002
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccineMarilisa Carsana, Gabrina Tragni, Gabriella Nicolini, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Nature Reviews. Clinical Oncology|July 9, 2014
Therapeutic vaccines for cancer: an overview of clinical trialsIgnacio Melero, Gustav Gaudernack, Winald Gerritsen, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2011
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyTonia Mazzarella, Valeria Cambiaghi, Nathalie Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 15, 2002
Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cellsMichele Maio, Ester Fonsatti, Elda Lamaj, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigenLuisa Novellino, Nicolina Renkvist, Francesca Rini, et al.
Pageof 11